Thalia Therapeutics
London, United Kingdom
◆ About Thalia Therapeutics
UK biotech company that raised €3.1 million and acquired Sanmirna Therapeutics.
◆ What sets it apart
Their Nuvec® platform based on amorphous silica uniquely enables multi-RNA loading and potential oral delivery, addressing critical RNA delivery inefficiencies.
◆ Sectors
Digital HealthBiotechDrug Discovery
◆ Business
Modeltransactional
Customerpharmaceutical companies, healthcare providers, and patients with oncology or cardiovascular diseases
◆ Notable
- Raised €3.1 million in funding
- Acquired Sanmirna Therapeutics
- Advancing a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a)
- Renamed from N4 Pharma plc to Thalia Therapeutics plc
◆ Explore the market
◆ FAQ
What does Thalia Therapeutics do?
UK biotech company that raised €3.1 million and acquired Sanmirna Therapeutics.
Where is Thalia Therapeutics based?
Thalia Therapeutics is based in London, United Kingdom, founded in 2025.